Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
For decades, LASIK was the default choice for vision correction. However, in 2026, the EVO ICL has emerged as a premium alternative that is capturing a larger share of the market. Rather than reshaping the cornea with a laser, the ICL is a micro-thin lens placed behind the iris, offering a surface-neutral option that doesn't compromise the ocular surface.
read more about ICL vs LASIK candidacy percentage ...In modern 2026 practices, approximately 20 percent of patients who initially ask for LASIK are deemed better candidates for ICL after screening. This shift is particularly pronounced in high-myopia populations (over -6.00D), where ICL adoption can reach 80 percent of total refractive cases as practitioners prioritize corneal integrity.
LASIK requires a certain amount of corneal thickness for the laser to safely reshape the tissue. Patients with thin corneas are often turned away from LASIK. Because ICL is surface-neutral—it does not remove or cut corneal tissue—it has a 100 percent success rate in providing safe correction for those previously told they were non-candidates.
Clinical data from 2026 confirms that ICL provides superior nighttime vision compared to high-prescription LASIK. Studies show 93.3 percent vision improvement with EVO ICL in high-myopia cases. Patients report fewer starbursts and halos during night driving because the ICL maintains the natural shape of the cornea.
LASIK involves cutting corneal nerves, which can induce or exacerbate dry eye in some patients. EVO ICL does not cut corneal nerves. 2026 surveys show that ICL shines with no induced dry eye, a major advantage for patients with dry eye histories or those who have misdiagnosed dry eyes that are actually contact lens intolerance.
In 2026, consumer preference for non-permanent medical changes is a growing trend. Unlike LASIK, which permanently removes corneal tissue, an ICL is removable and replaceable. Data shows that for younger patients, reversibility is a key decision factor, allowing the lens to be swapped out if vision needs change significantly later in life.
No. In 2026, the EVO ICL is made of Collamer, a biocompatible material that the body does not recognize as a foreign object. It is placed behind your iris (the colored part of your eye), so it is invisible to both you and anyone looking at you. It never moves, even if you rub your eyes.
While ICL is an intraocular procedure, 2026 safety data shows it is exceptionally safe. The primary risk is a lens-mismatch (sizing), but modern 3D topography and pupil measurement in 2026 have reduced this risk to under 2 percent. The procedure itself takes only minutes.
The ICL is designed to stay in your eye permanently. It does not wear out or degrade. However, because it is removable, it gives you the flexibility to have it replaced or removed if your vision needs change significantly or if you develop other eye health issues like cataracts in your late 70s or 80s.
Schedule a thorough pre-op exam (including topography and pupil measurement) to determine if you are a better candidate for LASIK or ICL. See your surgeon immediately if you experience halos, glare, or fluctuating vision after surgery, as these may indicate a need for a sizing adjustment.